OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for LusvertikimabDevelopment built on strong ...
Overall, the “Hidradenitis Suppuritiva Update 2026” session underscored a new treatment paradigm: HS care in 2026 requires early diagnosis, systemic screening, combination medical therapy, and ...
UCB Canada Inc. is pleased to announce Health Canada has granted a Notice of Compliance (NOC) for PrBIMZELX® (bimekizumab injection) indicated for the treatment of adult patients with moderate to ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
Tired of the flare-ups? Fortunately, topical antimicrobials like tea tree oil and targeted diet shifts, are gaining more and ...
In a pooled analysis of 25 studies from 23 countries, a two-question screening tool demonstrated excellent diagnostic ...
Canadians living with HS at risk of inequitable access to newly approved therapy, falling behind Australia, France, Germany, Scotland and other ...
Panelist discusses how hidradenitis suppurativa’s early detection is challenging due to misdiagnosis, patient stigma, and limited awareness. Improved physician education, proactive screening, and ...
In a study of 206 surgical procedures for hidradenitis suppurativa (HS), the overall recurrence rate was 18.5%. Two distinct recurrence patterns were identified — tunnel recurrence occurred in 8.3% of ...
Add Yahoo as a preferred source to see more of our stories on Google. Photo Credit: BG041/Bauer-Griffin/GC Images via Getty Images While Jeff Bezos and Lauren Sanchez enjoyed a spectacular Christmas ...
The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results